Msk colon cancer recurrence nomogram Diagnostic Pathway

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

MSKColon Cancer Freedom From Recurrence Nomogram

MSI / dMMR Colon Cancer

Bektas et al., JCO Clin Cancer Inform 2024 • C-index 0.812

T Category (Pathologic)

Number of Positive Lymph Nodes

N0 — No nodal involvement

Eligibility:AJCC Stage I–III MSI/dMMR colon cancer (cecum to rectosigmoid, >12cm from anal verge) after complete (R0) resection. Excludes: concurrent malignancy, metastatic disease, neoadjuvant therapy.

MSI Predictor

Enter T category and positive node count to compute 3- and 5-year freedom from recurrence.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Estimating individualized 5- and 10-year freedom from recurrence (FFR) after curative resection of non-metastatic (AJCC Stage I–III) colon cancer.

MSI-specific model: predicting 3- and 5-year FFR specifically in patients with microsatellite instability (MSI/dMMR) colon cancer, who have generally favourable outcomes but with a high-risk subgroup.

Counselling patients about adjuvant chemotherapy decisions by providing a more refined recurrence risk than conventional AJCC staging alone.

Clinical trial design: identifying high-risk patients suitable for novel adjuvant immunotherapy or chemotherapy trials.

Informing post-operative surveillance intensity and frequency based on individualised recurrence risk.

Last Comprehensive Review: 2026

In Recent Clinical News

MSK Colon Cancer Recurrence Nomogram

When to Use

When to Use

In Recent Clinical News

MSK Colon Cancer Recurrence Nomogram

When to Use

When to Use